zur Startseite
News/Publications

Ibrutinib in previously treated Waldenström´s macroglobulinemia.

Treon SP1, Tripsas CK, Meid K, Warren D, Varma G, Green R, Argyropoulos KV, Yang G, Cao Y, Xu L, Patterson CJ, Rodig S, Zehnder JL, Aster JC, Harris NL,Kanan S, Ghobrial I, Castillo JJ, Laubach JP, Hunter ZR, Salman Z, Li J, Cheng M, Clow F, Graef T, Palomba ML, Advani RH.
read more ›
 

Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus.

Dimopoulos MA1, Kastritis E1, Owen RG2, Kyle RA3, Landgren O4, Morra E5, Leleu X6, García-Sanz R7, Munshi N8, Anderson KC8, Terpos E1, Ghobrial IM8,Morel P9, Maloney D10, Rummel M11, Leblond V12, Advani RH13, Gertz MA3, Kyriakou C14, Thomas SK15, Barlogie B16, Gregory SA17, Kimby E18, Merlini G19,Treon SP8.
read more ›
 

Imprint

Impressum

 

Prof. Dr. C. Buske
Comprehensive Cancer Center Ulm
Institute of Experimental Cancer Research
University Hospital Ulm
James-Franck-Ring

89081 Ulm/Germany

  

 

 

 

phone:  +49-731-500 65 801
fax:        +49-731-500 65 822

 

Content responsible person in accordance to § 5 TMG and § 55 Abs. 2 RStV:
Prof. Dr. C. Buske (address as above)

 

Liability Note
Despite careful control we assume no liability for the content of external links. The content of the linked pages is the site operator’s responsibility.
 
Copyright
All images, logos and texts on these sites are property of “Comprehensive Cancer Center Ulm” and their partners. The reproduction and/or proliferation of the given content in any form require the written approval of “Comprehensive Cancer Center Ulm”.

Realisation

MJU.media Internetlösungen (www.mju-media.de)